Business
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer on Thursday, May 21, 2026, at
About this update from Black Diamond Therapeutics, Inc.
[{"type":"image","alt":"Black Diamond Therapeutics, Inc","displaySize":"","headline":null,"caption":"Black Diamond Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/497f244e89de775874fac406d50e11cb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PPufx14kfaWjle3J0KTo2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/497f244e89de775874fac406d50e11cb","width":300,"height":89},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/PPufx14kfaWjle3J0KTo2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/497f244e89de775874fac406d50e11cb","width":300,"height":89}},"lazy":false},{"type":"text","content":"Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET","length":60,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer on Thursday, May 21, 2026, at 5:30 p.m. ET.","length":452,"tagName":"p"},{"type":"text","content":"Webcast information","length":19,"tagName":"p"},{"type":"text","content":"The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event for a limited time.","length":251,"tagName":"p"},{"type":"text","content":"About Black Diamond Therapeutics","length":32,"tagName":"p"},{"type":"text","content":"Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-m...